Lakefront Biotherapeutics American Depositary Shares
LKFT
84 hedge funds and large institutions have $746M invested in Lakefront Biotherapeutics American Depositary Shares in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 21 increasing their positions, 34 reducing their positions, and 20 closing their positions.
245% more call options, than puts
Call options by funds: $6.94M | Put options by funds: $2.01M
1.88% less ownership
Funds ownership: 14.28% → 12.4% (-1.9%)
9% less funds holding
Funds holding: 92 → 84 (-8)
38% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 34
55% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 20
68% less capital inflows, than outflows
Capital inflows: $60.7M | Capital outflows: $190M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
+$21.3M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$16.3M |
| 3 |
Prosight Management
Dallas,
Texas
|
+$6.37M |
| 4 |
Deerfield Management
New York
|
+$2.87M |
| 5 |
Old Mission Capital
Chicago,
Illinois
|
+$1.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OrbiMed
New York
|
-$44M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$36.5M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$21.5M |
| 4 |
Laurion Capital Management
New York
|
-$14.4M |
| 5 |
Jane Street
New York
|
-$13.3M |
LKFT Hedge Fund Activity: Q4 2018 in Review
84 of the 4,504 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q4 2018, worth a combined $746M — down 30% from $1.06B a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of LKFT and 9 opened new positions — a net loss of 11 holders — while 34 trimmed existing stakes and 21 added.
The largest buyer was Bank of New York Mellon, adding an estimated $21.3M. The largest seller was OrbiMed, exiting entirely with an estimated $44M sold.
- 84 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q4 2018, down from 92 in Q3 2018.
- Funds reported $746M of Lakefront Biotherapeutics American Depositary Shares stock for Q4 2018, down 30% quarter-over-quarter.
- 9 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q4 2018 and 20 closed out, a net change of -11 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q4 2018 was Bank of New York Mellon, an estimated $21.3M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q4 2018 was OrbiMed, an estimated $44M sold.
Based on aggregated 13F filings for Q4 2018.